Roche Reports Results of Tecentriq + CT in P-III IMpassion031 Study for Patients with Early Triple-Negative Breast Cancer
Shots:
- The P-III IMpassion031 study involves assessing of Tecentriq + CT (Abraxane- nab-paclitaxel; followed by doxorubicin and cyclophosphamide) vs PBO + CT in 333 people in a ratio (1:1) with previously untreated- early TNBC- regardless of PD-L1 expression
- Results: met its 1EPs by demonstrating a clinically meaningful improvement in pathological complete response. Patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery- regardless of PD-L1 expression
- Tecentriq + nab-paclitaxel is currently approved in 70+ countries worldwide- including the US and across EU- for the treatment of adults with unresectable LA/metastatic TNBC in people whose tumors express PD-L1
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com